Trial Profile
A Pilot Study of Dovitinib as Maintenance and Adjuvant Therapy in Patients With Colorectal and Pancreas Cancers
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary)
- Indications Colon cancer; Pancreatic cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 13 Aug 2015 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to discontinued.
- 14 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 12 Feb 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.